Raloxifene, a new drug for breast cancer, waits for FDA approval

The Journal of the American Medical Association says that Raloxifene, an osteoporosis drug, is as helpful as tamoxifen. It cuts half the risk of breast cancer. Dr. Victor Vogel, of the University Of Pittsburgh School Of Medicine and his team has conducted the research on post-menopause women.

The researchers have found raloxifene reduces the risk of uterine cancers and blood clots. However, women who took tamoxifen during research suffered leg cramps, gynecological and bladder problems. On the other hand, women with raloxifene medication suffered with pain during sex and weight gain.

The Food and Drug Administration is yet to approve raloxifene for breast cancer prevention. The researchers are expecting this within a year or so.

Related Articles

Back to top button